Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Cancer Vaccines01:30

Cancer Vaccines

522
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
522
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research on optimization of C4 repair operation of Harmony electric locomotive based on preventive maintenance.

PloS one·2025
Same author

VaMIEL1-mediated ubiquitination of VaMYB4a orchestrates cold tolerance through integrated transcriptional and oxidative stress pathways in grapevine.

Horticulture research·2025
Same author

Transforming Prediction into Decision: Leveraging Transformer-Long Short-Term Memory Networks and Automatic Control for Enhanced Water Treatment Efficiency and Sustainability.

Sensors (Basel, Switzerland)·2025
Same author

Correction to "Tumor Cell Lysate-Based Multifunctional Nanoparticles Facilitate Enhanced mRNA Delivery and Immune Stimulation for Melanoma Gene Therapy".

Molecular pharmaceutics·2025
Same author

Amur Grape VaMYB4a-VaERF054-Like Module Regulates Cold Tolerance Through a Regulatory Feedback Loop.

Plant, cell & environment·2024
Same author

Bacterial Lysate-Based Bifunctional mRNA Nanoformulation for Efficient Colon Cancer Immunogene Therapy.

ACS applied materials & interfaces·2024

Related Experiment Video

Updated: Sep 19, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

Efficient cancer immunogenetherapy by tumor cell lysate modified mRNA formulation.

Jieping Wu1, Xizi Fu1, Xiaohua Chen1

  • 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.

Biomaterials
|June 9, 2025
PubMed
Summary

This study introduces a novel mRNA delivery system using tumor cell lysate (TLSV) for cancer therapy. TLSV effectively delivers mRNA, activates anti-cancer immune cells, and inhibits colon cancer, showing promise for tumor immunogenetherapy.

Keywords:
Cell lysateIL-17AImmunogene therapymRNA delivery

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

816

Related Experiment Videos

Last Updated: Sep 19, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

816

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Background:

  • mRNA-based gene therapy is crucial for cancer treatment.
  • Delivery systems often focus on efficiency, neglecting the vector's immunotherapeutic potential.
  • Tumor cell lysates offer immunostimulatory properties but face challenges in mRNA vector integration.

Purpose of the Study:

  • To develop a novel mRNA delivery system utilizing tumor cell lysate (TLSV).
  • To evaluate the immunotherapeutic capacity and anti-cancer efficacy of the TLSV system.
  • To investigate the activation of immune cells by the TLSV/IL-17A system.

Main Methods:

  • Construction of a tumor cell lysate-based mRNA delivery system (TLSV/IL-17A) encoding interleukin-17A mRNA.
  • Assessment of mRNA delivery efficiency in dendritic cells (DCs) and tumor cells.
  • Analysis of immune cell activation (pDCs, NK cells) and inhibition of colon cancer models.

Main Results:

  • TLSV demonstrated high mRNA delivery efficiency in DCs and tumor cells.
  • The system effectively activated plasmacytoid dendritic cells (pDCs) and natural killer (NK) cells, mounting a robust anti-cancer immune response.
  • TLSV/IL-17A significantly inhibited multiple colon cancer models.

Conclusions:

  • TLSV is a promising platform for mRNA delivery with inherent immunostimulatory properties.
  • The TLSV/IL-17A system exhibits significant therapeutic potential in colon cancer immunogenetherapy.
  • This approach highlights the importance of vector immunogenicity in mRNA-based cancer therapies.